Page 65 - Read Online
P. 65

Page 12 of 15                  Wu et al. Hepatoma Res 2023;9:6  https://dx.doi.org/10.20517/2394-5079.2022.37

               Conflicts of interest
               All authors declared that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2023.


               REFERENCES
               1.       Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36
                   cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.  DOI  PubMed
               2.       McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology 2021;73 Suppl 1:4-13.  DOI  PubMed
                   PMC
               3.       Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very
                   early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008;47:82-9.  DOI  PubMed
               4.       Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-
                   80.  DOI  PubMed
               5.       National Comprehensive Cancer Network. Hepatocellular cancer (Version 5.2021). Available from: https://www.nccn.org/
                   professionals/physician_gls/pdf/hepatobiliary.pdf [Last accessed on 10 Mar 2023].
               6.       Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves
                   survival. Hepatology 2003;37:429-42.  DOI  PubMed
               7.       Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol
                   2014;20:4115-27.  DOI  PubMed  PMC
               8.       Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J
                   Med 2008;359:378-90.  DOI  PubMed
               9.       Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced
                   hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.  DOI  PubMed
               10.      Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol
                   2022;76:681-93.  DOI  PubMed
               11.      Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
                   N Engl J Med 2020;382:1894-905.  DOI  PubMed
               12.      Abou-alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evidence
                   2022:1.  DOI
               13.      Sergio A, Cristofori C, Cardin R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role
                   of angiogenesis and invasiveness. Am J Gastroenterol 2008;103:914-21.  DOI  PubMed
               14.      Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular
                   carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J
                   Gastroenterol 2004;10:2878-82.  DOI  PubMed  PMC
               15.      Chen L, Sun J, Yang X. Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: current status. Cancer
                   Lett 2016;370:78-84.  DOI  PubMed  PMC
               16.      Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo) embolisation for unresectable hepatocellular carcinoma. Cochrane Database
                   Syst Rev 2011;(3):CD004787.  DOI  PubMed
               17.      Paul SB, Sharma H. Role of transcatheter intra-arterial therapies for hepatocellular carcinoma. J Clin Exp Hepatol 2014;4:S112-21.
                   DOI  PubMed  PMC
               18.      Miller FH, Lopes Vendrami C, Gabr A, et al. Evolution of radioembolization in treatment of hepatocellular carcinoma: a pictorial
                   review. Radiographics 2021;41:1802-18.  DOI  PubMed
               19.      Ahmed A, Stauffer JA, LeGout JD, et al. The use of neoadjuvant lobar radioembolization prior to major hepatic resection for
                   malignancy results in a low rate of post hepatectomy liver failure. J Gastrointest Oncol 2021;12:751-61.  DOI  PubMed  PMC
               20.      Lewandowski RJ, Gabr A, Abouchaleh N, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular
                   carcinoma. Radiology 2018;287:1050-8.  DOI  PubMed
               21.      Song MJ. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastroenterol 2015;21:3843-9.  DOI
                   PubMed  PMC
   60   61   62   63   64   65   66   67   68   69   70